MC0518 is named as an intervention in 2 current clinical trials in our Germany, France, Spain, Poland, Italy and Sweden registers. 1 is recruiting patients now. The most common phase is Phase 2. The lead sponsor is medac GmbH. The most-studied condition is Steroid-refractory Acute Graft-versus-host Disease. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy
NCT04629833 · ClinicalTrials.gov ↗ · Steroid-refractory Acute Graft-versus-host Disease
|
Phase 3 | Recruiting | medac GmbH | Germany, France, Spain, Sweden, Poland |
|
Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease
NCT06075706 · ClinicalTrials.gov ↗ · Steroid-refractory Acute Graft-versus-host Disease
|
Phase 2 | Active, closed | medac GmbH | Germany, France, Spain, Italy, Poland |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing MC0518. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
Efficacy of cell therapy with allo-MSCs in patients with gvhd resistant to ruxolitinib second line therapy: a Phase IIB Clinical Trial - MSC-GRR2 Study
2025-523448-10-00 · CTIS ↗ · Hemic and Lymphatic Diseases
|
Phase 2 | Authorised | Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia | Italy |
| Lead sponsor | Trials |
|---|---|
| medac GmbH | 2 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Germany | 2 | 1 |
| Clinical trials in France | 2 | 1 |
| Clinical trials in Spain | 2 | 1 |
| Clinical trials in Poland | 2 | 1 |
| Clinical trials in Italy | 1 | 0 |
| Clinical trials in Sweden | 1 | 1 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
2 current trials in our Germany, France, Spain, Poland, Italy and Sweden registers name MC0518 as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in Germany, 1 with sites in France, 1 with sites in Spain, 1 with sites in Poland and 1 with sites in Sweden. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is medac GmbH. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how MC0518 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how MC0518 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists MC0518 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.